Wells Fargo analyst Larry Biegelsen keeps an Overweight rating on DexCom (DXCM) with a $98 price target after the company disclosed that a warning letter was issued by the FDA following prior 483s. The warning letter did not identify any new observations that had not already been provided in the Form 483s previously issued to the company by the FDA at the conclusion of its two inspections in June and November 2024, the analyst tells investors in a research note. Wells sees no material impact to current DexCom production.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom warning letter ‘not thesis changing,’ says BofA
- Dexcom’s Resilience Amid FDA Warning: Buy Rating Affirmed by Analyst
- DexCom falls 7% to $71.99 after receiving warning letter from FDA
- DexCom receives warning letter from FDA, sees no impact to FY25 guidance
- Dexcom’s Strong Market Position and Growth Potential Drive Buy Rating and Price Target Increase